58
Participants
Start Date
December 31, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
TetraVax-DV Vaccine - Admixture TV003
One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
TetraVax-DV Vaccine - Admixture TV005
One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
Placebo
One SC injection at Day 0 and Day 180 of placebo
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore
Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington
University of Vermont Vaccine Testing Center, Burlington
National Institute of Allergy and Infectious Diseases (NIAID)
NIH